Abstract
The purpose of this guideline is to provide guidance on appropriate management of satellite and in-transit metastasis (itm) from melanoma. The guideline was developed by the Program in Evidence-Based Care (pebc) of Ontario Health (Cancer Care Ontario) and the Melanoma Disease Site Group. Recommendations were drafted by a Working Group based on a systematic review of publications in the medline and embase databases. The document underwent patient- and caregiver-specific consultation and was circulated to the Melanoma Disease Site Group and the pebc Report Approval Panel for internal review; the revised document underwent external review. "Minimal itm" is defined as lesions in a location with limited spread (generally 1-4 lesions); the lesions are generally superficial, often clustered together, and surgically resectable. "Moderate itm" is defined as more than 5 lesions covering a wider area, or the rapid development (within weeks) of new in-transit lesions. "Maximal itm" is defined as large-volume disease with multiple (>15-20) 2-3 cm nodules or subcutaneous or deeper lesions over a wide area.■ In patients presenting with minimal itm, complete surgical excision with negative pathologic margins is recommended. In addition to complete surgical resection, adjuvant treatment may be considered.■ In patients presenting with moderate unresectable itm, consider using this approach for localized treatment: intralesional interleukin 2 or talimogene laherparepvec as 1st choice, topical diphenylcyclopropenone as 2nd choice, or radiation therapy as 3rd choice. Evidence is insufficient to recommend intralesional bacille Calmette- Guérin or CO2 laser ablation outside of a research setting.■ In patients presenting with maximal itm confined to an extremity, isolated limb perfusion, isolated limb infusion, or systemic therapy may be considered. In extremely select cases, amputation could be considered as a final option in patients without systemic disease after discussion at a multidisciplinary case conference.■ In cases in which local, regional, or surgical treatments for itm might be ineffective or unable to be performed, or if a patient has systemic metastases at the same time, systemic therapy may be considered.
Highlights
According to Canadian Cancer Statistics[1,2], the projected number of cases of melanoma in Canada in 2017 was 7200 (18.5 per 100,000 population), with 1250 deaths, making melanoma the 8th most common cancer and the 15th in mortality
In-transit metastasis is a cutaneous or subcutaneous locoregional recurrence of disease that generally occurs in close proximity to the site of the primary lesion and travels toward the draining lymph node basin; satellite metastasis generally occurs within 2 cm of the primary lesion[4,5]
This guideline was developed by the Satellite and In-Transit Melanoma Guideline Development Group, which was convened at the request of the Melanoma Disease Site Group of oh(cco)
Summary
According to Canadian Cancer Statistics[1,2], the projected number of cases of melanoma in Canada in 2017 was 7200 (18.5 per 100,000 population), with 1250 deaths, making melanoma the 8th most common cancer and the 15th in mortality. In Ontario, 4129 cases of melanoma were predicted for 2018 (26.4 per 100,000 population), representing 4.6% of all cancers[3]. Actual data from 2013 indicated 3409 new cases of melanoma IN-TRANSIT METASTASIS IN MELANOMA, Wright et al. In patients diagnosed with melanoma, approximately 4%–10% will develop in-transit metastasis (itm) and satellite metastasis[4,5,6]. The term “itm” is considered to include satellite metastasis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.